FREE LECTURE: CMSS Presents: Preventive Medicine, Muslim Children and Our Community: World’s First Halal Vaccines – Globalvacc ‘Al Shifa’
|CMSS Presents: Preventive Medicine, Muslim Children and Our Community: World’s First Halal Vaccines – Globalvacc ‘Al Shifa’ : A public lecture by Mr VT Ragupathy
We have certainly come a long way in preventive medicine. Viruses are becoming more resistant and toxins continue to be the scourge of modern living. Although health and wellness may be on everyone’s minds these days, attention to wellbeing is by no means a new concept. People have been searching for ways to ‘stay in the pink’ since the dawn of civilisation. The field of medicine is vast but to what extent does it accommodate the needs of the Muslim word?
GLOBALVACC AL-SHIFA approved as world's first HIB Halal certified Preventive medicine for Muslim children and is the first step in giving the world Halal Vaccines. To integrate Halal concept into vaccines has been always a challenge because a lot of Pharmaceutical companies look at bottom lines and would not consider going the extra mile in sourcing for ingredients which are Halal. This lecture explores the journey towards developing the world's first HIB Halal certified Preventive medicine for Muslim children.
About the speaker:
Mr Ragupathy is a graduate of the National University of Singapore majoring in Molecular Biology and has 20 years of experience in the field establishing new technologies and innovations for large Pharmaceutical companies like Nestle, Pfizer, Roche, Lonza and Wyeth. He has worked on Biosensors, for in-vitro diagnostics use, in Nanyang Technological University using paramagnetic beads to detect organisms in different matrixes like blood, and other bodily fluids. He had set up the Pan B and Pan T Cells Separation Course for students in the National University of Singapore Microbiology Department, using DynaBeads (450nm ad 280 nm beads). He had worked on immuno-separation technology which has been adapted by Nestle for their Salmonella work. Together with Warwick University (UK), he did Real Time Microbial Load Monitoring in production plants manufacturing Infant formula (Nutraceuticals). Usage of flow-cytometry techniques with membrane bound dyes were used to develop this for Pfizer. In virology, he had developed a separation technology to aggregate Hep A virus which was 15 times more sensitive compared to then current methods. He has had previously worked in a R&D company called Singapore Biotech owned by Temasek Holdings co-developing with GSK Hepatitis Vaccines and locally produced Epstein Barr Virus kits. Mr Ragupathy is the CEO of KR Biologicals Pte Ld. which has been working with Serum Institute of India to launch the first Halal HIB vaccine for infants. He is also the Senior Vice-President of Innovative biotech and has also worked with distinguished scientists such as Dr Lance Gordan, who is the inventor and developer of the first bacterial conjugate vaccine to receive FDA and European approval.
- Locations of venues on the Crawley and Nedlands campuses are
available via the Campus Maps website.
- Download this event as:
Mail this event: